Clinical trial · Interventional
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Due to business reasons
Summary
Brief summary (as posted)
This is a Phase 1b/2 study of batiraxcept (AVB-S6-500) designed to evaluate the safety and efficacy of batiraxcept in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced, recurrent, or metastatic pancreatic adenocarcinoma as first line therapy. The phase 1b portion of the study is open label and patients will receive batiraxcept, nab-paclitaxel, and gemcitabine. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerability of batiraxcept, nab-paclitaxel, and gemcitabine versus nab-paclitaxel and gemcitabine as first line therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| batiraxcept | Drug | — | UNRESOLVED |
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| Nab paclitaxel | Drug | Nab-paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Phase 1b: batiraxcept+ nab-paclitaxel and gemcitabine
- description
- Up to three dose levels of bactiraxcept plus nab-paclitaxel and gemcitabine
- interventionNames
- Drug: batiraxcept
- Drug: Nab paclitaxel
- Drug: Gemcitabine
- type
- EXPERIMENTAL
- label
- Phase 2: batiraxcept+ nab-paclitaxel and gemcitabine
- interventionNames
- Drug: batiraxcept
- Drug: Nab paclitaxel
- Drug: Gemcitabine
- type
- ACTIVE_COMPARATOR
- label
- Phase 2: nab-paclitaxel and gemcitabine alone
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older * Histologically or cytologically confirmed pancreatic adenocarcinoma. Must have locally advanced, recurrent, or metastatic disease ineligible for curative intent treatment(s) and eligible for first line systemic treatment. * Must have radiologic imaging with a computed tomography (CT) scan or magnetic resonance imaging (MRI) within 22 days of study entry * Must have at least one measurable lesion according to RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Adequate gastrointestinal (GI), bone marrow, liver and kidney function * Life expectancy minimum of \> 12 weeks * Adequate recovery from surgery to Grade 1 or baseline with at least 28 days from time of major surgery Exclusion Criteria: * Received last dose of chemotherapy (neoadjuvant or adjuvant), surgery, or radiation treatment with curative intent within 6 months prior to study entry * Islet-cell neoplasms * Prior malignancy within the past 3 years except adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix, breast or melanoma * Symptomatic uncontrolled central nervous system (CNS) metastasis or brain metastases unless adequately treated and controlled * Evidence of clinically significant third spacing (e.g. pleural effusion, ascites, anasarca, etc.) within 28 days prior to study entry * Serious active infection requiring IV antibiotics and/or hospitalization at study entry * Active human immune deficiency (HIV) syndrome, hepatitis B, hepatitis C, or other active viral illness
References
Publications (0)
Data not yet available